Hong Suk Kyun, Kim Minseob, Kim Youngjin, Kim Jae-Yoon, Lee Jaewon, Kim Jiyoung, Hong Su Young, Lee Jeong-Moo, Choi YoungRok, Yi Nam-Joon, Lee Kwang-Woong, Suh Kyung-Suk
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Ann Hepatobiliary Pancreat Surg. 2024 Aug 31;28(3):337-343. doi: 10.14701/ahbps.24-020. Epub 2024 Apr 3.
BACKGROUNDS/AIMS: Challenges arise when translating pure laparoscopic donor right hepatectomy (PLDRH) results from Asian to Western donors, due to differences in body mass index (BMI). This study compares the outcomes of PLDRH and conventional open donor right hepatectomy (CDRH) in donors with BMI over 30.
Medical records of live liver donors (BMI > 30) undergoing right hepatectomy (2010-2021) were compared: 25 PLDRH cases vs. 19 CDRH cases. Donor and recipient demographics, operative details, and outcomes were analyzed.
PLDRH and CDRH had similar donor and recipient characteristics. PLDRH had longer liver removal and warm ischemic times, but a shorter post-liver removal duration than CDRH. Donor complication rates were comparable, with the highest complication being grade IIIa in PLDRH, necessitating needle aspiration for biloma on postoperative day 11. Fortunately, this donor fully recovered without additional treatment. No complications exceeding Clavien-Dindo grade IIIa occurred in either group. Recipient outcomes between the groups were similar.
This study supports PLDRH as a viable option for donors with BMI over 30, challenging the notion that high BMI should deter considering PLDRH. The findings provide valuable insights into the safety and feasibility of PLDRH, encouraging further exploration of this technique in diverse donor populations.
背景/目的:由于体重指数(BMI)存在差异,将单纯腹腔镜供体右半肝切除术(PLDRH)在亚洲供体中的结果应用于西方供体时会面临挑战。本研究比较了BMI超过30的供体中PLDRH与传统开放性供体右半肝切除术(CDRH)的结果。
比较了2010年至2021年期间接受右半肝切除术的活体肝供体(BMI>30)的病历:25例PLDRH病例与19例CDRH病例。分析了供体和受体的人口统计学特征、手术细节及结果。
PLDRH组和CDRH组的供体和受体特征相似。PLDRH组的肝脏切除时间和热缺血时间更长,但肝切除术后持续时间比CDRH组短。供体并发症发生率相当,PLDRH组最高并发症为Ⅲa级,术后第11天因胆汁瘤需进行穿刺抽吸。幸运的是,该供体未经额外治疗完全康复。两组均未发生超过Clavien-DindoⅢa级的并发症。两组受体的结果相似。
本研究支持PLDRH作为BMI超过30的供体的一种可行选择,挑战了高BMI应阻碍考虑PLDRH的观念。这些发现为PLDRH的安全性和可行性提供了有价值的见解,鼓励在不同供体人群中进一步探索该技术。